Our Pipeline

Pan-Amyloid Removal & Reversal Of The Underlying Pathology Of Systemic Amyloidosis

Making New Solutions Possible for Patients

AT ATTRALUS, WE SEE A CLEAR FUTURE WHERE MORE IS POSSIBLE FOR PATIENTS WITH SYSTEMIC AMYLOIDOSIS.

Using our proprietary pan-amyloid removal (PAR) technology, we are advancing a pipeline of novel therapeutics that remove toxic, disease-causing amyloid throughout the body with high specificity, and the potential to reverse disease pathology.  We are pioneering first-in-class novel pan-amyloid therapies that bind to all types of amyloid, so that our therapies can be used for patients with all types of systemic amyloidosis and at all stages of disease.

Why It Matters

There is a critical unmet need for disease modifying therapies that can remove amyloid across all stages and types of systemic amyloidosis. The existing approved drugs for amyloidosis do not address the toxic amyloid deposits that are present and accumulate in organs and are the cause of disease burden, progressive organ failure and increased mortality in patients.

Our Pioneering Pan-Amyloid Pipeline

With the aim to treat all types of patients with systemic amyloidosis and open the door to reversing disease, at Attralus we are advancing our pipeline of product candidates for pan-amyloid removal. We have designed our novel biologics to achieve pan-amyloid removal with superior amyloid binding and immune-mediated phagocytosis.

In support of our therapeutic strategy, we are also developing the world’s first amyloid-specific imaging agent which will improve the clinical journey for patients and dramatically expand the population of those who are diagnosed.

Program

Underlying Technology

Stage

Pre-clinical
IND-ENABLING
Phase 1
Phase 2
Therapeutics

AT-03

PAR-SAP
TECHNOLOGY
IND
ENABLING

AT-02

PAR-Peptide
TECHNOLOGY
LATE
PRE-CLINICAL

Peptide-immunoglobulin fusion

An icon representing that this technology is owned by Attralus

AT-04

PAR-Peptide
TECHNOLOGY
LATE
PRE-CLINICAL

Peptide-Fc fusion protein

An icon representing that this technology is owned by Attralus
Diagnostics

AT-01

PAN-Peptide
TECHNOLOGY
PHASE 2

Polybasic peptide radiotracer

An icon representing that this technology is owned by Attralus
P5+14 peptide
Base Platform Technology
More Info
An icon representing that this technology is owned by Attralus
Denotes that Attralus has commercial rights
Attralus has commercial rights to all 3 program technologies